|Bid||4.5500 x 1000|
|Ask||4.5900 x 1400|
|Day's Range||4.4400 - 4.6150|
|52 Week Range||2.2300 - 11.2000|
|Beta (5Y Monthly)||1.52|
|PE Ratio (TTM)||164.29|
|Earnings Date||Apr 30, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||20.67|
AVEO (AVEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AVEO Oncology (Nasdaq: AVEO) today announced that it has earned a $2.8 million development milestone payment from partner Kyowa Kirin Co., Ltd. (Kyowa Kirin). The milestone relates to acceptance by the Japanese Pharmaceuticals and Medical Devices Agency of an investigational new drug (IND) application for tivozanib in a non-oncology indication being developed by Kyowa Kirin.
Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today